Using the form, filter the technologies based on your search criteria. The results are based on the combined criteria.
The invention offers novel composition of matter to be used in treatment of a number of hormone responsive cancers.
Small molecule adjuvants that act as vaccine adjuvants by specifically binding to Toll-Like Receptor-8 (TLR8).
A three-dimensional tumor-in-dish (TID) cell-based assay kit for cancer drug screening that closely replicates actual cellular microenvironments and, therefore, can determine which compounds to move forward for in vivo testing.
This technology is a process for synthesizing low-dimensional hyperthin iron disulfide (FeS2) nanostructures to be used as electrocatalysts for hydrogen production through water-splitting reactions.
A novel anti-metastasis therapy for prostate cancer, utilizing the newly established small-activating RNA (saRNA) technique to up-regulate the expression of the tumor metastasis suppressor gene, dihydropyrimidase-like 3 (DPYSL3).
This device is an improvement on pre-existing technology. It is a nasoenteric feeding tube that is inexpensive, disposable, and designed to give the user more maneuverability and thus a better chance of successfully placing it in the small intestine.
The invention is a novel adaptive aero structure based on conventional, certified aerospace materials.
The invention provides novel compounds (adjuvants) that can be used as agonists for Toll-Like Receptor 7 (TLR7). By specifically targeting TLR7, these adjuvants elicit a type 1 interferon response which is essential in the development of antiviral responses.
KU research on the brain activity associated with low back pain led to the invention of a simple and cost-effective device that can be used to induce stimulation to a person's back during an fMRI scanning procedure.